FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308382005> ?p ?o ?g. }

• W4308382005 abstract "<h3>Background</h3> Immunocytokines can strengthen anti-PD-(L)1 therapy by promoting T-cell survival, but their shortened half-life and systemic toxicity limit their clinical development. We propose to selectively deliver IL-7 to PD-1⁺ T-cells using a bispecific anti-PD1/IL-7v mutein fused to reinvigorate PD1⁺IL-7R⁺ tumor-specific T cells and sustain long-term response. RNAseq and TILs scRNAseq analyses illustrate that IL-7R and IL-7R pathway gene expression is significantly correlated with better long-term OS and/or PFS across several cancers Higher IL-7R and IL-7R pathway expression by tumor-specific T-cell clonotype is significantly correlated with ICI response, higher stemness & proliferative signature,lower exhaustion and apoptosis markers, providing a strong rationale of co-targeting IL-7 to PD-1 to sustain durable tumor-specific T-cells response. Despite low IL-7R expression on Tumor-specific T-cell clonotype a high concentration of IL-7 can rescue them. We propose with the anti-PD-1/IL-7v to cis-target and provide a survival/proliferative specific signal. <h3>Methods</h3> Proliferation, IL-7R signaling assays were tested to determine the mechanism. For the suppressive assay, CD4 Treg and autologous CD8 Teff were co-cultured. In vivo experiments were performed in hPD-1KI immunocompetent mice. <h3>Results</h3> A high-affinity antagonist anti-PD-1 mAb was fused to a single IL-7 mutein (IL7v) having lower affinity to IL-7R complex allowing a preferential and optimal cis-potentiation of PD-1+ T-cells. Anti-PD1/IL7v restores proliferation and maintains long-term survival of chronically stimulated human T-cells in vitro (over 5 stimulation). scRNAseq and FACs analyses demonstrated that anti-PD1/IL7v triggers the expansion of TCF1+ stem-like memory T-cells (CCR7+PD1+KI67+), whereas IL-2 and IL-15 promote differentiation of T-cells into exhausted T-cells (TCF1-Tim3+Ki67+). Furthermore, anti-PD1/IL7v preferentially stimulated T_eff over T_reg as opposed to IL-2 & IL-15 and abrogated the T_reg suppression by restoring IFN-γ secretion and proliferation of CD8 T_eff. <i>In vivo</i>, anti-PD1/IL-7v has impressive monotherapy efficacy in PD-1 sensitive model (orthotopic mesothelioma,>90%CR) and in a PD-1 resistant model (orthotopic HCC,>65% CR) in which anti-PD-1 or IL-7 has no effect. Further analyses in HCC model demonstrate that anti-PD1/IL7v enhanced quality and biodistribution of T-cells by promoting intratumoral TCF1+CD8+stem-like T-cells proliferation and favoring T-cell migration into the tumor nest whereas anti-PD-1 promotes T-cell exclusion. Combination with sorafenib chemotherapy in HCC model further enhances in vivo efficacy. <h3>Conclusions</h3> Our data validate the rational of selective delivery of IL-7 to tumor-specific T-cells to sustain long-lasting response, proliferation, and survival of these key effectors upon ICI therapy. Anti-PD1/IL-7v preferentially cis-potentiates PD1+-tumor-specific-T-cells limiting the risk of I-O/I-O immunotoxicity and induces the expansion of stem-like T-cell capable to strengthen PD-1 therapy efficacy." @default.
• W4308382005 created "2022-11-11" @default.
• W4308382005 creator A5000095429 @default.
• W4308382005 creator A5012547336 @default.
• W4308382005 creator A5023411196 @default.
• W4308382005 creator A5029438699 @default.
• W4308382005 creator A5032120204 @default.
• W4308382005 creator A5048543389 @default.
• W4308382005 creator A5052078960 @default.
• W4308382005 creator A5075008701 @default.
• W4308382005 creator A5087659024 @default.
• W4308382005 date "2022-11-01" @default.
• W4308382005 modified "2023-10-17" @default.
• W4308382005 title "1366 Anti-PD-1/IL-7v bispecific antibody promotes TCF1+ stem like T cells expansion and long-lasting in vivo efficacy" @default.
• W4308382005 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1366" @default.
• W4308382005 hasPublicationYear "2022" @default.
• W4308382005 type Work @default.
• W4308382005 citedByCount "0" @default.
• W4308382005 crossrefType "proceedings-article" @default.
• W4308382005 hasAuthorship W4308382005A5000095429 @default.
• W4308382005 hasAuthorship W4308382005A5012547336 @default.
• W4308382005 hasAuthorship W4308382005A5023411196 @default.
• W4308382005 hasAuthorship W4308382005A5029438699 @default.
• W4308382005 hasAuthorship W4308382005A5032120204 @default.
• W4308382005 hasAuthorship W4308382005A5048543389 @default.
• W4308382005 hasAuthorship W4308382005A5052078960 @default.
• W4308382005 hasAuthorship W4308382005A5075008701 @default.
• W4308382005 hasAuthorship W4308382005A5087659024 @default.
• W4308382005 hasBestOaLocation W43083820051 @default.
• W4308382005 hasConcept C126322002 @default.
• W4308382005 hasConcept C150903083 @default.
• W4308382005 hasConcept C153911025 @default.
• W4308382005 hasConcept C167672396 @default.
• W4308382005 hasConcept C170493617 @default.
• W4308382005 hasConcept C185592680 @default.
• W4308382005 hasConcept C190283241 @default.
• W4308382005 hasConcept C203014093 @default.
• W4308382005 hasConcept C207001950 @default.
• W4308382005 hasConcept C2777371288 @default.
• W4308382005 hasConcept C502942594 @default.
• W4308382005 hasConcept C55493867 @default.
• W4308382005 hasConcept C71924100 @default.
• W4308382005 hasConcept C86803240 @default.
• W4308382005 hasConcept C8891405 @default.
• W4308382005 hasConceptScore W4308382005C126322002 @default.
• W4308382005 hasConceptScore W4308382005C150903083 @default.
• W4308382005 hasConceptScore W4308382005C153911025 @default.
• W4308382005 hasConceptScore W4308382005C167672396 @default.
• W4308382005 hasConceptScore W4308382005C170493617 @default.
• W4308382005 hasConceptScore W4308382005C185592680 @default.
• W4308382005 hasConceptScore W4308382005C190283241 @default.
• W4308382005 hasConceptScore W4308382005C203014093 @default.
• W4308382005 hasConceptScore W4308382005C207001950 @default.
• W4308382005 hasConceptScore W4308382005C2777371288 @default.
• W4308382005 hasConceptScore W4308382005C502942594 @default.
• W4308382005 hasConceptScore W4308382005C55493867 @default.
• W4308382005 hasConceptScore W4308382005C71924100 @default.
• W4308382005 hasConceptScore W4308382005C86803240 @default.
• W4308382005 hasConceptScore W4308382005C8891405 @default.
• W4308382005 hasLocation W43083820051 @default.
• W4308382005 hasOpenAccess W4308382005 @default.
• W4308382005 hasPrimaryLocation W43083820051 @default.
• W4308382005 hasRelatedWork W1524110646 @default.
• W4308382005 hasRelatedWork W2052210496 @default.
• W4308382005 hasRelatedWork W2063619316 @default.
• W4308382005 hasRelatedWork W2382765128 @default.
• W4308382005 hasRelatedWork W2414946262 @default.
• W4308382005 hasRelatedWork W2444613833 @default.
• W4308382005 hasRelatedWork W2748952813 @default.
• W4308382005 hasRelatedWork W2899084033 @default.
• W4308382005 hasRelatedWork W4238106566 @default.
• W4308382005 hasRelatedWork W2050030598 @default.
• W4308382005 isParatext "false" @default.
• W4308382005 isRetracted "false" @default.
• W4308382005 workType "article" @default.